December 17, 2018

IntegriChain Launches Life Sciences Commercial Data Refinery for Specialty and Retail Bio/Pharma Brands

“Data Enrichment 3.0” Employs Advanced Data Science to Boost Speed, Consistency, and Accuracy of Commercial Data and Analytics

Customizable Class of Trade Capability Delivers Integration Flexibility

Philadelphia, PA, December 17, 2018 – IntegriChain, a leading life sciences commercial data and analytics company that helps innovative bio/pharma manufacturers identify and remove barriers to patient therapy initiation and adherence, today announced a significant data science advancement for its life sciences commercial data and analytics platform with the launch of the IntegriChain Data Refinery for its Payer, Patient, and Distribution solutions. The Data Refinery capitalizes on fully automated metadata processes and advanced machine learning to deliver Data Enrichment 3.0,  the next-generation of data enrichment, to improve the efficiency, consistency, accuracy, and adaptability of key commercial datasets for specialty and retail bio/pharma brands.

“Bio/pharma manufacturers face considerable commercial data visibility challenges due to a changing landscape of distribution practices, consolidation in the retail channel, and wholesaler reporting changes,” said William Van Derveer, Executive Director of IntegriChain’s Data Factory Operations. “Our new high-performance and highly scalable Data Refinery is designed to overcome today’s and tomorrow’s  access challenges. The Data Refinery leverages the deep experience and expertise of our world-class data science team. The data visibility we can now deliver through the Data Refinery powers the IntegriChain insights and analytics engine, allowing our more than 140 customers to identify and overcome barriers to helping patients start and stay on therapy.”

Comprising a hub combined with data cleansing, data enrichment, and IntegriChain’s unsurpassed data mastering capabilities, the Refinery will be implemented in IntegriChain’s Payer, Patient, and Distribution solutions on January 1, 2019, for current and new customers. As part of this enhancement, IntegriChain also now delivers Customizable Class of Trade, providing more integration flexibility to bio/pharma manufacturers. This enhancement offers manufacturers the ability to match their own internal location identifiers to IntegriChain’s Point-of-Care Master, allowing the integration of the manufacturer’s identifiers and classes of trade with their commercial data.

About IntegriChain
IntegriChain is a life sciences commercial data and analytics company that helps innovative bio/pharma manufacturers identify and remove barriers to patient therapy initiation and adherence. Our mission is to help all stakeholders in pharmaceutical access save as many patient days of therapy as possible. The InteriChain ICyte Platform and solutions uniquely focus on access challenges after the patient and provider commit to therapy. More than 140 life science manufacturers rely on insights delivered from IntegriChain’s data, analytics, and managed services to drive strategic decision-making and on-going business management across their payers, specialty pharmacies, patient services, and distribution channel partners. IntegriChain is backed by Accel-KKR, a leading Silicon Valley technology private equity firm. The company is headquartered in Philadelphia, PA; the Access Management Operations center is in Ambler, PA; and the Patient Services Center is in Atlanta, GA. For more information, visit www.integrichain.com or follow us on Twitter @IntegriChain and LinkedIn.

Contact
Jennifer Guinan | Sage Strategic Marketing | 610.410.8111 | Jennifer@sagestrat.com